The α7 nAChR is therefore considered a promising drug target for the treatment of cognitive symptoms in patients with schizophrenia or Alzheimer’s disease, and this has led to an intensive drug development effort to produce α7 nAChR selective agonists and positive allosteric modulators (reviewed in [11]). This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.